{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:53:51Z","timestamp":1773863631398,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The FDA has approved Talazoparib and Enzalutamide for metastatic castration\u2010resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutations, based on the TALAPRO\u20102 Phase 3 trial. This study developed and validated an LC\u2010MS\/MS method for simultaneous quantification of Talazoparib and Enzalutamide in rat plasma using Apalutamide as the internal standard. Chromatographic separation was achieved with a 70:30 (v\/v) acetonitrile\u20130.1% formic acid system, 10\u2009min runtime, and 1.0\u2009mL\/min flow rate. Retention times were 4.13\u2009min (Talazoparib), 5.31\u2009min (Enzalutamide), and 7.89\u2009min (Apalutamide). Detection was performed in positive ionization mode using MRM transitions:\n                    <jats:italic>m<\/jats:italic>\n                    \/\n                    <jats:italic>z<\/jats:italic>\n                    381.35\u2009\u2192\u2009240.56, 465.44\u2009\u2192\u2009305.24, and 478.44\u2009\u2192\u2009285.10, respectively. The method was linear over 0.05\u20132\u2009ng\/mL for Talazoparib and 4\u2013160\u2009ng\/mL for Enzalutamide (\n                    <jats:italic>r<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009&gt;\u20090.999). Accuracy and precision were within \u00b115%\u201320%, and recovery exceeded 98%. In pharmacokinetic studies on male Wistar rats, Talazoparib showed a\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    of 0.88\u2009ng\/mL at 3\u2009h and an AUC\n                    <jats:sub>\n                      0\u2212\n                      <jats:italic>t<\/jats:italic>\n                    <\/jats:sub>\n                    of 20\u2009ng\u00b7h\/mL, while Enzalutamide exhibited a\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    of 76.18\u2009ng\/mL at 1\u2009h and an AUC\n                    <jats:sub>\n                      0\u2212\n                      <jats:italic>t<\/jats:italic>\n                    <\/jats:sub>\n                    of 1702\u2009ng\u00b7h\/mL; both had 24\u2009h half\u2010lives. The validated method enables sensitive, rapid, and reliable bioanalysis for preclinical pharmacokinetic evaluation.\n                  <\/jats:p>","DOI":"10.1002\/bmc.70381","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:08:27Z","timestamp":1770120507000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Validated LC\u2010MS\/MS Method for Quantification and Pharmacokinetic Analysis of Talazoparib and Enzalutamide in Rats"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7000-9426","authenticated-orcid":false,"given":"Rajesh","family":"Guntupalli","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Biotechnology and Pharmaceutical Sciences Vignan's Foundation for Science, Technology &amp; Research  Guntur Andhra Pradesh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4450-5732","authenticated-orcid":false,"given":"Panchumarthy","family":"Ravisankar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis Vignan Pharmacy College  Guntur Andhra Pradesh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8250-3570","authenticated-orcid":false,"given":"Sathish\u00a0Kumar","family":"Konidala","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Biotechnology and Pharmaceutical Sciences Vignan's Foundation for Science, Technology &amp; Research  Guntur Andhra Pradesh India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)00684\u20101"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25105071"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002704\u2010x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11094\u2010023\u201002904\u20102"},{"key":"e_1_2_10_6_1","unstructured":"Hanson Robert.Hanson R.(2023).Targeting DNA Repair in Prostate Cancer: Therapeutic Combinations & Disease Models(Doctoral dissertation).https:\/\/doi.org\/10.17863\/CAM.102133."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40543\u2010021\u201000276\u20104"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4046"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1952181"},{"key":"e_1_2_10_10_1","unstructured":"Compendium of CPCSEA:2025https:\/\/ccsea.gov.in\/WriteReadData\/userfiles\/file\/Compendium%20of%20CPCSEA.pdf."},{"key":"e_1_2_10_11_1","unstructured":"FDA Guidelines:2018https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical\u2010Method\u2010Validation\u2010Guidance\u2010for\u2010Industry.pdf."},{"key":"e_1_2_10_12_1","unstructured":"Animal Welfare:2025https:\/\/www.pci.nic.in\/pdf\/15.pdf."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215417"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2022.07.058"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.02.018"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2016.08.036"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12013\u2010022\u201001075\u20103"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2020.03.002"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.15583\/jpchrom.2015.029"},{"issue":"3","key":"e_1_2_10_20_1","first-page":"321","article-title":"Pharmacokinetic Characterization of Enzalutamide in Preclinical Models","volume":"42","author":"Papadopoulos K. P.","year":"2015","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"key":"e_1_2_10_21_1","unstructured":"Pfizer Inc.2020Clinical Pharmacology and Pharmacokinetics of Talzenna (Talazoparib)https:\/\/www.pfizermedical.com\/patient\/talzenna\/clinical\u2010pharmacology."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2017.04.014"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25102448"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.5599\/admet.557"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/1177390117726776"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.8266559"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.5530\/ijpi.13.2.036"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010015\u20100271\u20105"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.3127"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20972"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061849"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.25135\/jcm.2310.2937"},{"key":"e_1_2_10_33_1","unstructured":"US Food and Drug Administration.2023.FDA Approves Talazoparib With Enzalutamide for HRR Gene\u2010Mutated Metastatic Castration\u2010Resistant Prostate Cancer."},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15300"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/sscp.70119"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.112850"},{"issue":"1","key":"e_1_2_10_37_1","article-title":"UPLC\u2010MS\/MS Method and Pharmacokinetic Study of Talazoparib in Rat Plasma","volume":"33","author":"Zhao L.","year":"2019","journal-title":"Biomedical Chromatography"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10337\u2010018\u20103611\u20104"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.70381","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bmc.70381","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.70381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:23:31Z","timestamp":1773836611000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.70381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/bmc.70381"],"URL":"https:\/\/doi.org\/10.1002\/bmc.70381","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"2025-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70381"}}